New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...

Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ...

In a further sign of growing interest among large drugmakers in an emerging target for cancer immunotherapy drugs, a company in the space is getting an equity investment from one of the world’s ...

Researchers from the USC Norris Comprehensive Cancer Center and collaborators report that they have found evidence that targeting CD47, a protein that is part of the innate immune system, could be a ...

A characteristic of tumors includes the ability to avoid the immune system. In many cases tumors can progress without detection of immune cells. In the literature many scientists refer to undetectable ...

ALX Oncology (NASDAQ:ALXO) outlined progress across its two clinical-stage programs—CD47 blocker evorpacept and EGFR-targeted ...

A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in ...